Patents by Inventor Damian Wild

Damian Wild has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [161 tb]-based radiopeptides
    Patent number: 12208145
    Abstract: A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.
    Type: Grant
    Filed: February 21, 2023
    Date of Patent: January 28, 2025
    Assignees: Universität Basel, Paul Scherrer Institute
    Inventors: Cristina Müller, Roger Schibli, Nicholas Philip Van Der Meulen, Francesca Borgna, Damian Wild, Melpomeni Fani
  • [161Tb]-BASED RADIOPEPTIDES
    Publication number: 20240181094
    Abstract: A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.
    Type: Application
    Filed: October 29, 2021
    Publication date: June 6, 2024
    Inventors: Cristina MÜLLER, Roger SCHIBLI, Nicolas VAN DER MEULEN, Francesca BORGNA, Damian WILD, Fani MELPOMENI
  • [161Tb]-BASED RADIOPEPTIDES
    Publication number: 20230293736
    Abstract: A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.
    Type: Application
    Filed: February 21, 2023
    Publication date: September 21, 2023
    Inventors: Cristina Müller, Roger Schibli, Nicolas Philip Van Der Meulen, Francesca Borgna, Damian Wild, Melpomeni Fani
  • [161Tb]-BASED RADIOPEPTIDES
    Publication number: 20230165981
    Abstract: A radiopeptide is provided which comprises (a) a radionuclide, wherein the radionuclide is terbium-161, (b) a chelator coordinating terbium-161, and (c) a peptide or peptide analogue, which is a somatostatin receptor (SSTR) antagonist. The radiopeptide is suitable for use in the treatment of tumor diseases.
    Type: Application
    Filed: September 29, 2022
    Publication date: June 1, 2023
    Inventors: Cristina Müller, Roger Schibli, Nicolas Philip Van Der Meulen, Francesca Borgna, Damian Wild, Melpomeni Fani